MRNA logo

MRNA

Moderna Inc.

$42.55
-$1.52(-3.45%)
59
Overall
60
Value
66
Tech
52
Quality
Market Cap
$10.81B
Volume
16.10M
52W Range
$22.28 - $55.20
Target Price
$37.40

Company Overview

Mkt Cap$10.81BPrice$42.55
Volume16.10MChange-3.45%
P/E Ratio-3.0Open$43.45
Revenue$3.2BPrev Close$44.07
Net Income$-3.6B52W Range$22.28 - $55.20
Div YieldN/ATarget$37.40
Overall59Value60
Quality52Technical66

No chart data available

About Moderna Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology

Latest News

Moderna’s CMV Vaccine Extension Study Reaches Completion, Setting the Stage for Next Growth Catalyst

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna’s latest clinical update centers on a long‑term extension of its cytom...

TipRanks Clinical-Trials-Auto-Generated Newsdesk16 hours ago

SNDK, MU, CRM: January’s Best and Worst-Performing Stocks

Joel Baglole2 days ago

Moderna Stock Slips As Ambitious Cancer Trials Drag On

TipRanks Weekend Auto-Generated Newsdesk3 days ago

SPY ETF Daily Update, 1/28/2026

Radhika Saraogi6 days ago

Vanguard S&P 500 ETF (VOO) Daily Update, 1/27/2026

Shalu Saraf7 days ago
ABCD
1SymbolPriceChangeVol
2MRNA$42.55-3.4%16.10M
3
4
5
6

Get Moderna Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.